§ Federal grant opportunity · HT942526OCRPOCCTAECI
DoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award
Christopher Meinberg Grantor is accepting applications for DoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award. The deadline is October 1, 2026 and the published award range is Award amount not published.
Key facts
- Funder
- Christopher Meinberg Grantor
- Application deadline
- October 1, 2026
- Award range
- Award amount not published
- Eligibility
- Eligibility criteria are published in the funding opportunity announcement.
- Geography
- United States
- Focus areas
- Research
- Opportunity number
- HT942526OCRPOCCTAECI
Program overview
Summary: Created in FY23, the Ovarian Cancer Clinical Trial Academy (OCCTA) supports the next generation of Early-Career Investigators (ECIs) in clinical trial research to produce effective treatments and cures for ovarian cancer. The OCCTA, through its Leadership, provides for professional and leadership development of the ECIs to include skills and competencies needed to execute clinical trials, providing intensive mentoring, national networking, collaborations, and a peer group for junior clinical trialists. The OCCTA will bring together established investigators (the Academy Dean and Assistant Dean), established Career Guides (mentors), and a group of ECIs/Scholars to conduct successful, highly productive clinical trials in ovarian cancer. Distinctive Features: Research funded under this FY26 funding opportunity will support translational research and small-scale, early-phase clinical trials in ovarian cancer. Preliminary data are required, however, these data do not necessarily need to be derived from the ovarian cancer research field. The ECI must be within 12 years of their last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent at the time of full application submission deadline. The ECI must commit no less than 25% effort to this award and/or OCCTA activities for the first two years. The Designated Mentor must be a clinical trialist with a strong record of mentoring and training early-career investigators.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from Christopher Meinberg Grantor.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before October 1, 2026, allowing time for registration and validation.
Related grant opportunities
- Limited Competition: Growing Great Ideas: Research Education Course in Entrepreneurship and Product Development for Researchers Studying Drug Use, Drug Misuse, and Drug Addiction (UE5 Clinical Trial Not Allowed)
- DoW Ovarian Cancer, Clinical Trial Award
- DoW, Ovarian Cancer, Pilot Award
- Novel Experiential Technologies Assisting Individual Learning (NExT AI) Hubs (P20 Clinical Trial Optional)
- Sheep Production and Marketing Grant Program FY 2026
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.